Molecular Partners and Novartis COVID-19 Antiviral Candidate, Ensovibep, Maintains Binding and Neutralization of New Viral Variants in vitro
South Africa in the news: Molecular Partners and Novartis COVID-19 Antiviral Candidate, Ensovibep, Maintains Binding and Neutralization of New Viral Variants in vitro: New study shows that Molecular Partners’ tri-specific antiviral DARPin® candidates, ensovibep (MP0420) and the Company’s preclinical candidate, MP0423, remain therapeutically active against the known …: “South Africa” – BingNews International travel had …